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Abstract
Objective: The Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire is a disease- specific instrument developed to
measure quality of life (QoL) in patients with psoriatic arthritis (PsA). The aim of this study was to translate the measure into
Dutch and to determine its psychometric properties.
Method: Translation of the original English PsAQoL into Dutch was performed by bilingual and lay panel. Ten field-test
interviews with PsA patients were performed to assess face and content validity. In total, 211 PsA patients were included in
a test-retest postal survey to investigate the reliability and construct validity of the Dutch adaptation of the PsAQoL. The
PsAQoL, Health Assessment Questionnaire (HAQ) and Skindex-17 were administered on two different occasions
approximately two weeks apart.
Results: The Dutch version of the PsAQoL was found to be relevant, understandable and easy to complete in only a few
minutes. It correlated as expected with the HAQ (Spearman’s r= 0.72) and the 2 subscales of the Skindex-17 (r= 0.40 for the
psychosocial and r= 0.46 for the symptom scale). Furthermore, the measure had good internal consistency (Cronbach’s
a= 0.92) and test-retest reliability (r= 0.89). The PsAQoL was able to define groups of patients based on self-reported
general health status, self-reported severity of PsA and flare of arthritis. Duration of PsA did not influence PsAQoL scores.
Conclusions: The Dutch version of the PsAQoL is a valid and reliable questionnaire suitable for use in clinical or research
settings to asses PsA-specific QoL.
Citation: Wink F, Arends S, McKenna SP, Houtman PM, Brouwer E, et al. (2013) Validity and Reliability of the Dutch Adaptation of the Psoriatic Arthritis Quality of
Life (PsAQoL) Questionnaire. PLoS ONE 8(2): e55912. doi:10.1371/journal.pone.0055912
Editor: Masataka Kuwana, Keio University School of Medicine, Japan
Received August 1, 2012; Accepted January 4, 2013; Published February 13, 2013
Copyright:  2013 Wink et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have read the journal’s policy and have the following conflict: co-author professor McKenna is Director of Research and CEO
at Galen Research, which is the leading European developer of quality of life instruments for use in clinical trials and health economic studies. This does not alter
the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: f.r.wink@umcg.nl
. These authors contributed equally to this work.
Introduction
Psoriatic arthritis (PsA) is an inflammatory arthritis associated
with psoriasis. PsA is characterized by synovitis, dactylitis,
enthesitis and spondylitis. The clinical presentation can vary
between asymmetrical oligoarthritis, symmetrical polyarthritis or
spondyloarthritis. Skin lesions precede the arthritis in most cases.
In approximately 15–20% of patients, arthritis is the first
presenting symptom (PsA sine psoriasis) [1,2].
PsA influences the physical and mental status of the patient.
Therapy in patients with PsA focuses on both the improvement of
symptoms and functioning and on improvement of quality of life
(QoL). The most commonly operationalised definition of QoL in
health outcomes research is the needs-based model [3]. This
model sees QoL as the extent to which a patient is able to meet his
or her needs. Symptoms and activity limitations are only
important where they prevent needs from being met. QoL is
good when most needs are met and poor when disease and/or its
treatment prevents need fulfilment. Consequently, QoL is
a unidimensional construct, as has been shown by the de-
velopment of several disease-specific QoL measures [4–8].
Different outcome measures have been used to attempt to
evaluate the total impact of PsA. Generic health status instruments
such as the Health Assessment Questionnaire (HAQ), the Arthritis
Impact Measurement Scale (AIMS) and the 36-item Short Form
Health Survey (SF-36) are most commonly used. These generic
questionnaires predominantly focus on impairment and disability
rather than QoL, and their responsiveness has been reported to be
limited in PsA [9]. Treatment of PsA with anti-tumour necrosis
factor-alpha (TNF-a) blocking agents has been shown to improve
QoL in general [10]. The HAQ and SF-36 were used to determine
the effect of the intervention, but neither questionnaire actually
assesses QoL. To assess changes in outcome associated with
interventions accurately, standardized and validated disease-
specific instruments are required in PsA. McKenna et al. have
developed and validated the PsAQoL questionnaire to fulfil this
need [11]. As this instrument was developed with United
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Kingdom (UK) patients, it requires adaptation for use in other
countries. The PsAQoL has recently been adapted for use in
several countries for inclusion in international clinical trials but
only the Swedish adaptation has been published to date [12]. Prior
to the development of the PsAQoL, similar disease-specific
questionnaires have been developed and validated for rheumatoid
arthritis (RAQoL) [7] and ankylosing spondylitis (ASQoL) [6].
Both questionnaires were developed and validated simultaneously
in the Netherlands and the United Kingdom.
The method used to translate all needs-based QoL instruments
involves the use of 2 panels, involving native people actually living
in the target country. The value of the commonly used translation
method – forward and backward translation – has been questioned
[13] and there is no evidence supporting its use [14]. In the only
head to head study comparing the two panel method with forward
and backward translation, the former was shown to produce
translations that are more acceptable to patients [15].
The aim of the present study was to translate the English version
of the PsAQoL into Dutch and to determine its psychometric
properties.
Methods
Three stages of the Dutch adaptation of the PsAQoL were
performed. Stage 1 included the translation of the original
PsAQoL, stage 2 the field-testing of the translated version of the
PsAQoL and stage 3 the test-retest postal survey of the PsAQoL.
Stage 1: Translation of the PsAQoL
The two panel methodology was applied to produce the Dutch
PsAQoL. This approach has been used in the adaptation of all
needs-based QoL instruments [5,8,11]. A bilingual panel working
together agreed on the best Dutch translations for the instructions
and items. The questionnaire was then presented to a lay panel for
consideration. This panel was employed to ensure that the
language being used in the final version would be understood by
potential respondents and that it was in everyday Dutch. This
resulted in the first Dutch draft of the PsAQoL.
Stage 2: Field-testing
Ten interviews were conducted with PsA patients individually to
determine face and content validity of the candidate version of the
PsAQoL. The interviewer was present during the completion of
the questionnaire and determined afterwards whether the in-
terviewee found any problems with the measure, if it was relevant
to them and if any important issues were missing. Time taken to
complete the PsAQoL was also recorded for each patient.
Stage 3: Test-retest Postal Validation Survey
Patients. 289 patients diagnosed with PsA at the outpatient
clinic of the Medical Center Leeuwarden were consecutively
selected out of the Diagnosis Treatment Combination (DTC)-
system from 2009. The DTC-system is a model in which hospitals
are paid on a casemix-based tariff for the entire treatment of
a patient in the hospital during 1 year. Every DTC, chosen by the
medical specialist, has a unique performance code that refers to
the clinical diagnosis. Inclusion criteria were fulfilling the
Classification criteria of Psoriatic Arthritis (CASPAR) and being
over 18 years of age. The selected group of patients contained
early as well as established PsA, with early PsA being defined as
diagnosed in the previous 2 years and established PsA as diagnosed
more than 2 years previously.
All patients received an information letter about the study
together with an informed consent form. Patients who did not take
the initiative to return the informed consent form were phoned
and asked if they wanted to participate in the study. Patients were
excluded from the study if no informed consent was given, they
were unable to read Dutch or they were legally incapable.
The regional medical ethics committee at Leeuwarden stated
that ethics committee approval was not necessary for the study,
because the questions on medical information were minimized and
used only for calculating the known-groups validity. They
concluded that this validation did not fall under the law ‘Medical
Scientific Research’.
Internal consistency. Internal consistency was assessed by
Cronbach’s a coefficient. A value of at least 0.70 indicates
adequate inter-relatedness of items [16].
Test-retest reliability. The test-retest reliability of an in-
strument is based on the assumption that the construct has not
changed over time and thus the outcome of the measure can be
reproduced.
To test the reproducibility of the PsAQoL over time, the
questionnaire was completed by the same patients on 2 different
occasions approximately 2 weeks apart. This standard time period
was chosen because it is unlikely that the disease status will change
in this short period which is also long enough to avoid recall of
responses. A correlation of 0.85 or above indicates that the
measure has good reproducibility [17].
Construct validity. The PsAQoL consists of 20 yes/no
questions derived directly from qualitative interviews conducted
with UK PsAQoL patients [11]. The total score is calculated as the
number of questions affirmed and can range from 0 to 20. A high
total score indicates a poor quality of life.
Convergent validity of the PsAQoL was evaluated by correlat-
ing the PsAQoL scores with those obtained on the HAQ and
Skindex-17.
The HAQ measures functional limitations in arthritic disease.
The HAQ is a generic instrument that uses a four-point scale to
rate performance on 20 tasks. These tasks are grouped in 8
domains: dressing, rising, eating, walking, hygiene, reaching, grip
and everyday activities. Score on the HAQ is calculated by adding
the highest score of each of the eight domains and dividing by 8.
This gives the functional disability index which can range from 0 to
3.
The HAQ focuses on physical aspects of disease and has been
shown to be incapable of measuring the impact of skin lesions in
PsA [18]. The Skindex-17 questionnaire was included in the
survey to capture the impact of psoriasis. Skindex-17 is a Rasch
reduced version of the Skindex-29 and consists of 2 subscales (12
psychosocial items and 5 symptom items) [19]. The original 5-
point response scale of the Skindex-29 was changed into a 3-point
response format. The 2 subscales have separate summing scores,
ranging from 0–24 in the psychosocial and from 0–10 in the
symptom subscale.
Known-group validity was determined by the degree to which
an instrument can demonstrate different scores for groups thought
to vary on the factors measured by the scale. Demographic data
and information on perceived general health (very good, good, fair
or poor), severity of PsA (mild, moderate, severe or very severe)
and self-reported flare of arthritis and/or psoriasis during the last 3
months as well as time since diagnosis (early versus established
PsA) were collected by a questionnaire and were used to
investigate this known group validity.
Statistical Analysis
Statistical analysis was performed using PASW Statistics 18
(SPSS, Chicago, IL, USA).
Dutch Adaptation PsAQoL Questionnaire
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The Spearman correlation coefficient was calculated between
scores on the 2 administrations of the PsAQoL to determine test-
retest reliability. In addition, a Bland-Altman analysis was
performed and visualized in a plot to show differences between
the first and second assessments of PsAQoL scores.
Construct validity was examined by calculating Spearman’s
correlation coefficients (r) between the PsAQoL scores and those
Table 1. Characteristics of the psoriatic arthritis (PsA) study population.
Number of patients 183A 175B 134C 156D
Male gender (n, %) 101 (55) 99 (57) 74 (55) 86 (55)
Age (y) (mean 6 SD) 55.4612.5 55.1612.7 56.3612.3 54.9612.6
Married/cohabitting (n, %) 126 (69) 121 (69) 103 (77) 109 (70)
Employment (n, %) Full-time 47 (26) 45 (26) 34 (25) 41 (26)
Part-time 31 (17) 31 (18) 27 (20) 29 (19)
Retired 31 (17) 28 (16) 26 (19) 24 (15)
Housekeeper 12 (7) 11 (6) 10 (8) 11 (7)
Other 29 (16) 28 (16) 26 (19) 25 (16)
Missing 33 (18) 32 (18) 11 (8) 26 (17)
Duration of PsA (y) (median, range) 5.5 (0.3–45) 5.3 (0.3–45) 5.6 (0.3–45) 5.5 (0.3–45)
Current flare of arthritis (n, %) 27 (15) 25 (14) 24 (18) 23 (15)
Current flare of psoriasis (n, %) 19 (10) 17 (10) 16 (12) 15 (10)
Perceived general health (n, %) Very good 6 (3) 6 (3) 6 (5) 6 (4)
Good 71 (39) 68 (39) 56 (42) 64 (41)
Fair 67 (37) 65 (37) 57 (43) 55 (35)
Poor 8 (4) 6 (3) 6 (5) 6 (4)
Missing 31 (17) 30 (17) 9 (7) 25 (16)
Perceived severity of arthritis (n, %) Mild 62 (34) 58 (33) 47 (35) 55 (35)
Moderate 65 (36) 67 (38) 58 (43) 59 (38)
Severe 17 (9) 16 (9) 16 (12) 14 (9)
Very severe 2 (1) 2 (1) 2 (2) 2 (1)
Missing 37 (20) 32 (18) 11 (8) 26 (17)
Current treatment for arthritis (n, %) 133 (73) 127 (73) 111 (83) 123 (79)
DMARD 115 (63) 109 (62) 96 (72) 96 (62)
Anti-TNFa 27 (15) 25 (14) 21 (16) 22 (14)
NSAIDs 29 (16) 27 (15) 24 (18) 26 (17)
Missing 35 (19) 34 (19) 13 (10) 30 (19)
Current treatment for psoriasis (n, %) 57 (31) 53 (30) 45 (34) 46 (30)
Data obtained from self-reports.
A = responders 1st series of questionnaires;
B = 1st series PsAQoL complete; used for internal con- sistency assessment;
C = 1st and 2nd series PsAQoL complete; used for calculating test-retest reliability;
D = 1st series PsAQoL, HAQ and Skindex complete; used for convergent validity analyses.
PsA, psoriatic arthritis; n, number; y, years; SD, standard deviation; DMARD, disease-modifying antirheumatic drugs; anti-TNFa, anti-tumor necrosis factor a; NSAID, non-
steroidal anti- inflammatory drug; PsAQoL, psoriatic arthrtitis quality of life; HAQ, health assessement questionnaire.
doi:10.1371/journal.pone.0055912.t001
Table 2. Scores on the PsAQoL, HAQ and Skindex-17 at first and second assessment.
PsAQoL HAQ Skin-17 Psychosocial scale Skin-17 Symptom scale
1st 2nd 1st 2nd 1st 2nd 1st 2nd
N 175 141 170 130 174 143 177 145
Median 5.00 5.00 0.25 0.38 2.00 2.00 4.00 4.00
Range 0–20 0–20 0–3.0 0–2.9 0–24 0–24 0–10 0–10
PsAQoL, psoriatic arthritis quality of life; HAQ, health assessment questionnaire; Skin-17, Skindex-17; N, number of patients.
doi:10.1371/journal.pone.0055912.t002
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on the HAQ and on the 2 subscales (psychosocial and symptom
scale) of the Skindex-17. It was hypothesized that there would be
moderate correlations between scores on these measures as they
assess related but different types of outcome. Correlations between
0.5 and 0.7 indicate moderate correlation. The Mann-Whitney U
test was used to compare differences between groups. Differences
between both assessments were tested using the Wilcoxon signed
rank test. P values ,0.05 were considered statistically significant.
Results
Three stages of the validation of the Dutch PsAQoL were
performed. First, the original English PsAQoL was translated into
Dutch. Second, the field testing of the candidate version of the
PsAQoL was performed. And last, the internal consistency, test-
retest reliability and construct validity were obtained in a test-
retest postal survey.
Stage 1: Translation of the PsAQoL
The bilingual panel consisted of 3 females and 2 males, aged 24
to 59 years. They worked together on the translation of the
original PsAQoL items into Dutch.
The translation of 5 items was straightforward. Fifteen other
items raised some discussion (7 items) or could not be translated
easily (8 items), because some English expressions do not exist in
Dutch or because some English words have more than one Dutch
translation. The expert panel changed the answer categories from
true/not true to yes/no, because yes and no are more frequently
used in Dutch questionnaires.
There were 3 females and 3 males, aged 24 to 62 years in the lay
panel, all of whom had an average level of education. The lay
panel was asked to review the Dutch questions on their un-
derstandability. Unclear words and/or sentences were discussed
until consensus was reached. If it was thought to be necessary,
changes to words were made without losing the essence of the
item.
Stage 2: Field Testing
Individual interviews were conducted with 5 male and 5 female
PsA patients, aged 39 to 79 years. Self-reported severity of PsA and
general health ranged from mild to very severe and from poor to
very good, respectively. The purpose of the interview was clear to
all patients and they found the questionnaire clear and easy to
complete. The mean time needed to complete the PsAQoL was 4
(standard deviation (SD) 62) minutes with a range from 2 to 10
minutes. Median PsAQoL score was 10.5, with a range from 0 to
14.
Five patients suggested missing aspects of QoL in the PsAQoL.
Two respondents argued that the influence of PsA on sexual life
Table 3. Internal consistency and test-retest reliability of
PsAQoL.
PsAQoL
1st assessment 2nd assessment
Median (range) 5.8 (0–20) 5.8 (0–20)




PsAQoL, psoriatic arthritis quality of life; CI, confidence interval.
doi:10.1371/journal.pone.0055912.t003
Figure 1. Bland-Altman plot PsAQoL. Difference between the 1st and 2nd PsAQoL plotted against the mean of both assessments. PsAQoL,
Psoriatic Arthritis Quality of Life; LOA, limits of agreement; CI, confidence interval.
doi:10.1371/journal.pone.0055912.g001
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was important although one of these pointed out that it would be
too personal to ask about sexual life in such a questionnaire. Other
aspects reported to be missing from the questionnaire were related
to impairment and activity limitations rather than QoL or to the
opinion of other people regarding their disease.
One respondent stated that it would have been better to use
questions rather than statements. All but one patient considered
the questionnaire relevant, while another thought that some items
were similar. No items were thought to be inappropriate or
otherwise unacceptable. Finally, one patient considered some
items to be too general.
After reviewing the comments of the interviewed patients with
PsA, it was not found necessary to make adjustments to the
wording of the Dutch PsAQoL.
Stage 3: Test-retest Postal Survey
Patients. Of the 289 selected patients, 211 (73%) were
included in the study. Most of the excluded patients chose not to
participate in the study (n = 61), while 15 patients did not respond
to the information letter or to several phone calls. One patient was
severely mentally impaired and another was excluded because of
difficulties with answering questionnaires. The gender (54% male),
age (mean 51.9 years) and disease duration (median 6.6 years) of
the excluded patients did not differ significantly from that of the
included patients.
183 of 211 (86.7%) patients completed and returned the first set
of questionnaires. Of these, 145 (79.2%) returned completed
questionnaires on the second administration. Characteristics of the
validation survey population are shown in Table 1.
Thirty patients had early PsA, 119 had established PsA and the
time of diagnosis was not known for 34 patients. Of the 133
patients receiving treatment for their PsA, 63% were being treated
with Disease Modifying Anti-Rheumatic Drug (DMARD), most
frequently being methotrexate and less often salazopyrine,
leflunomide or hydroxychloroquine. Fifteen percent of patients
were receiving anti-TNF-a treatment.
Scores on the outcome measures. Table 2 shows the scores
on the PsAQoL, HAQ and Skindex-17 at first and seond
assessments. The median PsAQoL score was 5, with a range from
0–20, at both assessments. The scores on the other 2 ques-
tionnaires were also relatively low with a wide range.
Internal consistency. The Cronbach’s a coefficient for the
Dutch version of the PsAQoL was 0.92, indicating adequate inter-
relations between the items of the questionnaire (Table 3).
Test-retest reliability. Test-retest reliability of the Dutch
version of the PsAQoL was 0.89, demonstrating very good
reproducibility. Bland-Altman analyses showed that the mean
Table 4. Convergent validity of the PsAQoL.
HAQ Skin-17 Psychosocial scale Skin-17 Symptom scale
PsAQoL 1st assessment 0.72* 0.40* 0.46*
PsAQoL, psoriatic arthritis quality of life; HAQ, health assessment questionnaire; Skin-17, Skindex-17.
*P,0.01.
doi:10.1371/journal.pone.0055912.t004
Figure 2. Known-group validity of the PsAQoL visualized in Box-and-Whisker plots (Tukey). Boxes indicate medians with interquartile
ranges;+indicate means; whiskers indicate 1.5 times the interquartile distances;N indicate outliers. A = general health, B = severity of psoriatic arthritis,
C = exacerbation of arthritis. PsAQoL, Psoriatic Arthritis Quality of Life; GH, general health; PsA, psoriatic arthritis.
doi:10.1371/journal.pone.0055912.g002
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difference between the first and second assessment of the PsAQoL
was small (except for 1 patient) and did not significantly differ from
zero. Consequently, no systematic bias was found between the
administrations. Furthermore, the plot was evenly spread around
the mean (middle line) (Figure 1). The limits of agreement (LOA)
of the PsAQoL were found between -5.3 and 5.1 out of a total of
20.
Construct validity. The PsAQoL correlated moderately
with the HAQ (r=0.72) and low to moderately with the two
subscales of the Skindex-17 (r=0.40 for the psychosocial scale and
r=0.46 for the symptom scale) (Table 4).
Females scored significantly higher on the PsAQoL than men
(median 6.0 vs 2.5, p,0.05). No correlation was found between
age and PsAQoL scores was found (r=0.01, p= 0.923).
Scores on the PsAQoL were related to self-reported general
health and severity of PsA and whether or not they were
experiencing a flare of their arthritis and/or psoriasis, confirming
known-group validity. Patients rating their general health as fair or
poor scored significantly higher on the PsAQoL than patients who
rated their health good or very good. Respondents perceiving their
PsA to be severe or very severe scored significantly higher on the
PsAQoL than patients rating their PsA mild or moderate. Patients
reporting a flare of their arthritis also had significantly higher
scores on the PsAQoL compared to patients without a flare
(Figure 2). Time since diagnosis did not significantly influence the
PsAQoL scores as was expected (median 5.0 for early PsA vs 3.0
for established PsA; p = 0.537). Changing the definition of early
PsA in diagnosed in the previous 5 years did not alter these results
(data not shown). No statistically significant differences in PsAQoL
score were found for patients reporting a flare of psoriasis
compared to patients not reporting a flare (median 6.5 vs 3.0,
p = 0.122).
Discussion
The Dutch version of the PsAQoL was found to be relevant,
understandable and easy to complete in only a few minutes. It
showed good internal consistency, reproducibility and construct
validity.
The good internal consistency of the PsAQoL found in the
present study is in line with the findings of the original
development study of the PsAQoL and the adaptation study of
the Swedish PsAQoL [11,12]. Also, reproducibility was found to
be good in all 3 studies. The moderate correlation of the PsAQoL
to the HAQ and Skindex-17 reflect the fact that these measures
only assess one facet of PsA and that they measure different types
of patient-reported outcome.
The PsAQoL was able to distinguish patients perceiving worse
self-reported general health or more severe PsA. Also patients
experiencing an exacerbation of arthritis could be discriminated.
The duration of the PsA did not affect the score on the PsAQoL.
These results are in accordance with the studies in the UK and
Sweden [3,12]. Both studies also found differences in PsAQoL
score based on (self-reported) general health and exacerbation of
arthritis. Perceived severity of PsA was related to the PsAQoL
score in the original PsAQoL study [3]. Both studies did not
demonstrate differences in score related to time since diagnosis of
the PsA.
PsAQoL scores in this study were low compared to scores in the
PsAQoL developmental study reported by McKenna et al [11],
but similar to those found in the Swedish study [12]. The median
in the present study was 5 versus 9 in the original publication and
5.8 in the Swedish study. In both adaptation studies, approxi-
mately 20% of the patients scored the minimum whereas only 1%
scored the maximum. The low scores on the PsAQoL in this study
probably reflect the relatively mild disease in the sample studied.
In the present study, 72% of the patients reported their PsA as
being mild or moderate and 42% rated their general health to be
good or very good. In the UK study, 63% of the patients classified
their arthritis as mild or moderate. The numbers of flares of
arthritis and psoriasis was low in this study (15% and 10%)
compared to both the original PsAQoL study (54% and 41%) and
the Swedish study (47% and 45%) [11,12]. Treatment for arthritis
was given in 73% of patients in both this and the UK PsAQoL
validation population. The difference in the severity of PsA in the
Swedish and present study compared to the UK study might be
partly explained by the increase in use of biological treatment in
PsA.
In the OMERACT 8 (Outcome Measures in Rheumatoid
Arthritis Clinical Trials), a PsA module was included which led to
a core set of 6 domains, one of these being health-related QoL
[20]. While the PsAQoL assesses QoL rather than health-related
QoL, it has the advantage that the needs-based measurement
model copes well with the presence of both skin and joint related
problems.
Sensitivity to change is an important requirement for outcome
measures. To determine whether the PsAQoL could detect
significant change over time Healy and Helliwell [21] analysed
the responsiveness to change of the PsAQoL in a group of 28
patients with active PsA. They found a standardized response
mean (SRM) of 0.71 at 3 months and of 0.41 at 6 months. Similar
rates of change for Patient Global VAS and the HAQ were found
(which have both been validated for PsA). Before the PsAQoL can
be used in intervention studies, further research is necessary to
evaluate the sensitivity to change of the PsAQoL.
Marzo-Ortega et al. [22] published a small clinical trial in
which they used the PsAQoL as a secondary outcome measure. At
20 weeks there was a significant improvement in PsAQoL scores
for patients with active PsA treated with infliximab and
methotrexate.
In conclusion, the present study showed that the Dutch version
of the PsAQoL is valid and reliable. Patients found the
questionnaire relevant, understandable and easy to administer,
taking about 4 minutes to complete. These results suggest that the
PsAQoL can be a relevant questionnaire for use with PsA patients
in Dutch clinical and research settings.
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